Akademik Veri Yönetim Sistemi
48th Annual Meeting of European Society for Blood and Marrow Transplantation, 19 - 23 Mart 2022, cilt.57, sa.300, ss.264
Background: covlD-19 has resulted in high morbadity and
mortality among hematopoietic 5tem ce|| tran5plant (HcT)
recapients and CAR T cell treated patients. These population have
therefore been regarded a5 high priority for Vaccination. Little i5
known of the severity and outcome of covlD-]9 contracted after
Vaccination. The lDwP has collected data on this topjc through the
continuin9 prospective data co|lection on patients with covlD-'I9.
Thi5 abstract 5ummarizes culrent resultr.
Methods: The EBMT registry has collected information on covlD-
19 infection 5ince end of February 2020. ln February 2021 q uestions
regarding covl}19 vaccinations were added. To date, the.e9i5try
has received reports on 28 patients contracting covlD-ı9 after the
date ofthe first vaccine do5e.20 patients were after allo HcT,6 after
auto HcT, and 2 had received cAR T ce|l5. The median age was 54.5
year5 (20-74). ]1/20 allo HcT patients had active GVHD and 10
received immunosuppre5sion at lhe time of covlDı9,
Re5ult§: The median time from the first vaccine dose to
diagnosis of covlD 19 was 24 days (2 - 242 daylJ. ]0 patients
required hospjtaljzation while ı6 wele caled for as out-patients
(data missing = 2). Fou. patients .equİed lcu (data mi5sing for 2
patients) and fiVe patients died. For all 5 patients, the primary
cause of death was coVlDJg. Four patient5 were treated with
monoclonal antibodie5 and one with hyperimmune plasma. out of
patients receiving one dose of vaccine, 7/]4 (50%) were
hospitalized, 4/14 (28.60/o) required lCU, and 5/16 (31.270) died
including the patient, who had received one dose just before the
HCT. Two patients having received one dose had not resolved
covlD-19 at the time of reponing. of patients receiving two doses
of vaccine, 3/12 \25ok) were hospitalized, none requjred lcu or
died, and all covl}19 infections had resolved. The ovelall survival
probability was 79.1% at 6-week from the diagnosis of covlD-l9.
Excluding the patients Vaccinated before HCT the suryival
plobability at 6 weeks wa§ 81.69o. The survival was superior in
patients having received two doses (Fig. 1). concluslons: Two doses of any vaccine against covlD-]g
lesulted in lower risks for complications lequirin9 lcu and death.
Therefore, it is of uttermost importance to pursue vaccinations of
HcT and cAR T cell treated patients.